GLPwatch
Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
Can J Ophthalmol · 2017
Last updated 2026-05-28| Journal | Can J Ophthalmol, 2017 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Full record and abstract on PubMed 29074013 ↗